Abstract
The therapeutic effect of mizoribine (MZR) on spontaneous autoimmune disorders in MRL/Mp-lpr/lpr (MRL/l) mice was investigated. Mice were administered MZR for 3 days a week, orally, from 8 to 20 weeks of age. MZR at a dose of 20 mg/kg had a beneficial effect on the lesions in lupus nephritis and arthritis, histopathologically. At a dose of 40 mg/kg, MZR prevented the appearance of dermatitis, the lymphoproliferation of lymph nodes, reduced serum anti-dsDNA antibody titer, IgG-rheumatoid factor and anti-sheep red blood cells immune response. MZR increased number of both T cells and B cells form rosettes with SRBC. These findings provide evidences that MZR is applicable to human autoimmune diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
